Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 100 |
| Active Pipeline (Recruiting Now) | 43 (20) |
| Completed vs Stopped Early | 13 / 4 (4.0%) |
| Median Closed Actual Enrollment | 44 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Yonsei University Health System, Severance Hospital | Seoul | 34 |
| Severance Hospital | Seoul, Seoul,50-1 Yonsei-ro/Seodaemun-gu | 17 |
| Severance Hospital, Yonsei University Health System | Seoul, Other | 8 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06516679 | Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Yonsei University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.